Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» melanoma
melanoma
How Far Into the Drug Pipeline Should the FTC Reach?
TheStreet.com
Mon, 05/1/17 - 10:59 am
FTC
GSK
Novartis
BRAF inhibitor
MEK inhibitor
melanoma
Array Biopharma
M&A
Bristol-Myers Squibb says cancer drug combination 'significantly' improved survival in late-stage melanoma trial
Marketwatch
Tue, 04/4/17 - 11:01 pm
Bristol-Myers Squibb
Opdivo
Yervoy
melanoma
Why NewLink Genetics Shares Fell 10.3% Today
Motley Fool
Tue, 04/4/17 - 11:00 pm
NewLink Genetics
indoximod
melanoma
For Bristol-Myers, A Victory And A Mystery
Forbes
Mon, 04/3/17 - 11:44 am
Bristol-Myers Squibb
Opdivo
melanoma
Merck, Incyte Expand Cancer Collaboration
Barron's
Fri, 03/31/17 - 10:00 pm
Merck
Incyte
epacadostat
Keytruda
melanoma
Array walks back its FDA pitch on binimetinib, derailing plans for commercial launch
Endpoints
Mon, 03/20/17 - 09:35 am
Array Biopharma
FDA
binimetinib
NRAS-positive melanoma
melanoma
Roche flags early success for Tecentriq combos, hustles into PhIIIs
Endpoints
Mon, 11/7/16 - 09:10 pm
Tecentriq
Roche
clinical trials
melanoma
New Bristol-Myers Squibb Research on Opdivo (nivolumab) Monotherapy and in Combination With Yervoy (ipilimumab) at SMR 2016 Congress Reinforces Immuno-Oncology Leadership and Scientific Expertise in Melanoma
Yahoo
Mon, 10/31/16 - 09:08 am
Bristol-Myers Squibb
Opdivo
Yervoy
melanoma
These 3 Little Biotechs Just Scored Big
Motley Fool
Tue, 10/11/16 - 09:33 pm
biotech
Celldex Therapeutics
melanoma
glemba
Exelixis
Cabometyx
renal cell carcinoma
Tesaro
ovarian cancer
niraparib
3 Cancer Drugs That Could Get an FDA OK Next Year
Motley Fool
Mon, 10/10/16 - 09:02 am
FDA
rucaparib
Clovis Oncology
ovarian cancer
binimetinib
Array Biopharma
melanoma
brigatinib
Ariad Pharmaceuticals
non-small cell lung cancer
Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
Yahoo
Sat, 10/8/16 - 03:53 pm
Merck
Keytruda
melanoma
Opdivo: The Oncology Blockbuster for Bristol-Myers Squibb
Market Realist
Tue, 08/23/16 - 09:55 am
Opdivo
Bristol-Myers Squibb
melanoma
lung cancer
Celldex Rose on Phase 2 Melanoma Data
Market Realist
Wed, 06/8/16 - 05:06 pm
Celldex
melanoma
CDX‑1401
CDX-301
New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Yahoo
Sun, 06/5/16 - 11:57 am
Keytruda
Merck
ASCO 2016
melanoma
Merck, Bristol drugs show longer survival for deadly cancers
Yahoo/Reuters
Thu, 05/19/16 - 09:59 am
Merck
Bristol-Myers Squibb
cancer immunotherapy
lung cancer
melanoma
Opdivo
Keytruda
ASCO 2016
Keytruda: Merck’s New Blockbuster for Its Immuno-Oncology Franchise
Yahoo/Market Realist
Sun, 03/6/16 - 11:33 am
Keytruda
Merck
immuno-oncology
melanoma
non-small cell lung cancer
Pharma's Big New Cancer Drug May Be an Old Red Dye
Fortune
Fri, 02/26/16 - 03:21 pm
cancer
Provectus Biopharmaceuticals
melanoma
BMS' Opdivo evens the score in melanoma with two new FDA green lights
Fierce Pharma
Mon, 01/25/16 - 10:32 pm
Bristol-Myers Squibb
Opdivo
FDA
melanoma
Bristol-Myers' Opdivo Gets Nod for Melanoma From U.K. Regulator
Bloomberg
Thu, 01/21/16 - 07:52 pm
Bristol-Myers Squibb
Opdivo
melanoma
UK
NICE
Amgen wins quick EU approval for Imlygic, its first-in-class immuno-oncology drug
Fierce Pharma
Sun, 12/20/15 - 04:32 pm
Amgen
Europe
Imlygic
melanoma
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »